Characterization of a method using viable human target cells as the solid phase in a cell concentration fluorescence immunoassay (CCFIA) for screening of monoclonal antibodies and hybridoma supernatants.

[1]  R. Oldham,et al.  Therapeutic murine monoclonal antibodies developed for individual cancer patients. , 1989, Journal of biological response modifiers.

[2]  R. Wahl,et al.  A semi-automated fluorescent (SAF) assay using viable, whole cells for screening hybridoma supernatants. , 1987, Journal of immunological methods.

[3]  W. Marshall,et al.  Glutaraldehyde fixation of target cells to plastic for ELISA assays of monoclonal anti-HLA antibodies produces artefacts. , 1986, Journal of immunological methods.

[4]  M. Krantz,et al.  Monoclonal antibody recognizing human melanoma-carcinoma cross-reacting oncofetal antigen epitopically associated with carcinoembryonic antigen. , 1985, Journal of the National Cancer Institute.

[5]  R. Wahl,et al.  Dot-based ELISA and RIA: two rapid assays that screen hybridoma supernatants against whole live cells. , 1984, Journal of immunological methods.

[6]  D. Kelso,et al.  Particle concentration fluorescence immunoassay (PCFIA): a new, rapid immunoassay technique with high sensitivity. , 1984, Journal of immunological methods.

[7]  A. Fisher,et al.  A rapid method for determining whether monoclonal antibodies react with the same or different antigens on the cell surface. , 1980, Journal of immunological methods.

[8]  J. Douillard,et al.  Enzyme-linked immunosorbent assay for screening monoclonal antibody production: use of intact cells as antigen. , 1980, Journal of immunological methods.

[9]  C. Sorg,et al.  Use of an enzyme-linked immunosorbent assay (ELISA) for screening of hybridoma antibodies against cell surface antigens. , 1980, Journal of immunological methods.

[10]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.